Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00700102 · OUTCOME

Response Rate: Participants With Response Status Based on RECIST Criteria

A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. · Source last updated 2015-07-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
within 6.5 years

What was measured

Response Evaluation Criteria In Solid Tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.

Analysis population: Participants with measurable disease

Groups in this outcome

Chemotherapy

Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal

Chemotherapy + Bevacizumab

Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Chemotherapy406
Chemotherapy + Bevacizumab404

Reported measurements

Complete response
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Chemotherapy0.5Not reported0.11.8Not reported
Chemotherapy + Bevacizumab0.2Not reported0.01.4Not reported
Partial response
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Chemotherapy3.4Not reported1.95.7Not reported
Chemotherapy + Bevacizumab5.2Not reported3.27.8Not reported
Stable Disease
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Chemotherapy50.2Not reported45.355.2Not reported
Chemotherapy + Bevacizumab62.6Not reported57.767.4Not reported
Progressive Disease
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Chemotherapy35.0Not reported30.339.8Not reported
Chemotherapy + Bevacizumab21.5Not reported17.625.9Not reported
Missing (No Response Assessment)
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Chemotherapy10.8Not reportedNANAMissing data not analyzable
Chemotherapy + Bevacizumab10.4Not reportedNANAMissing data not analyzable
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.1
        upper Limit
        1.8
        value
        0.5
      2. group Id
        OG001
        lower Limit
        0.0
        upper Limit
        1.4
        value
        0.2
    title
    Complete response
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.9
        upper Limit
        5.7
        value
        3.4
      2. group Id
        OG001
        lower Limit
        3.2
        upper Limit
        7.8
        value
        5.2
    title
    Partial response
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        45.3
        upper Limit
        55.2
        value
        50.2
      2. group Id
        OG001
        lower Limit
        57.7
        upper Limit
        67.4
        value
        62.6
    title
    Stable Disease
  4. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        30.3
        upper Limit
        39.8
        value
        35.0
      2. group Id
        OG001
        lower Limit
        17.6
        upper Limit
        25.9
        value
        21.5
    title
    Progressive Disease
  5. categories
    1. measurements
      1. comment
        Missing data not analyzable
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        10.8
      2. comment
        Missing data not analyzable
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        10.4
    title
    Missing (No Response Assessment)
denoms
  1. counts
    1. group Id
      OG000
      value
      406
    2. group Id
      OG001
      value
      404
    units
    Participants
description
Response Evaluation Criteria In Solid Tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.
dispersion Type
95% Confidence Interval
groups
  1. description
    Chemotherapy alone until disease progression, unacceptable toxicity, or patient refusal
    id
    OG000
    title
    Chemotherapy
  2. description
    Chemotherapy and Bevacizumab until disease progression, unacceptable toxicity, or patient refusal
    id
    OG001
    title
    Chemotherapy + Bevacizumab
param Type
NUMBER
population Description
Participants with measurable disease
reporting Status
POSTED
time Frame
within 6.5 years
title
Response Rate: Participants With Response Status Based on RECIST Criteria
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice